- Home
- IMCR vs AMPL Comparison
IMCR vs AMPL Comparison
Compare IMCR & AMPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- AMPL
- Stock Information
- Founded
- IMCR 2008
- AMPL 2012
- Country
- IMCR United Kingdom
- AMPL United States
- Employees
- IMCR N/A
- AMPL N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- AMPL EDP Services
- Sector
- IMCR Health Care
- AMPL Technology
- Exchange
- IMCR Nasdaq
- AMPL Nasdaq
- Market Cap
- IMCR 1.7B
- AMPL 1.7B
- IPO Year
- IMCR 2021
- AMPL 2021
- Fundamental
- Price
- IMCR $34.26
- AMPL $10.03
- Analyst Decision
- IMCR Buy
- AMPL Buy
- Analyst Count
- IMCR 9
- AMPL 10
- Target Price
- IMCR $57.00
- AMPL $14.10
- AVG Volume (30 Days)
- IMCR 287.1K
- AMPL 1.4M
- Earning Date
- IMCR 11-05-2025
- AMPL 11-05-2025
- Dividend Yield
- IMCR N/A
- AMPL N/A
- EPS Growth
- IMCR N/A
- AMPL N/A
- EPS
- IMCR N/A
- AMPL N/A
- Revenue
- IMCR $356,145,000.00
- AMPL $316,571,000.00
- Revenue This Year
- IMCR $29.71
- AMPL $15.04
- Revenue Next Year
- IMCR $11.27
- AMPL $12.93
- P/E Ratio
- IMCR N/A
- AMPL N/A
- Revenue Growth
- IMCR 26.78
- AMPL 9.93
- 52 Week Low
- IMCR $23.15
- AMPL $7.55
- 52 Week High
- IMCR $39.33
- AMPL $14.88
- Technical
- Relative Strength Index (RSI)
- IMCR 49.34
- AMPL 35.14
- Support Level
- IMCR $33.92
- AMPL $9.98
- Resistance Level
- IMCR $37.00
- AMPL $10.52
- Average True Range (ATR)
- IMCR 1.45
- AMPL 0.46
- MACD
- IMCR -0.06
- AMPL -0.16
- Stochastic Oscillator
- IMCR 39.78
- AMPL 5.21
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About AMPL Amplitude Inc.
Amplitude Inc is a Software company that provides a Digital Analytics Platform that helps companies analyze their customer behavior within digital products. The Company delivers its application over the Internet as a subscription service using a software-as-a-service (SaaS) model and also it offers customer support related to initial implementation setup, ongoing support services, and application training. The company generates revenue primarily through selling subscriptions to the platform. The company derives a majority of its revenue from the United States.